首页> 外文期刊>World Allergy Organization Journal >Section 1. EPR-3 versus GINA 2008 Guidelines - Asthma Control and Step 3 Care: Highlights of the Asthma Summit 2009: Beyond the Guidelines
【24h】

Section 1. EPR-3 versus GINA 2008 Guidelines - Asthma Control and Step 3 Care: Highlights of the Asthma Summit 2009: Beyond the Guidelines

机译:第1节EPR-3与GINA 2008指南-哮喘控制和第3步护理:2009年哮喘峰会的重点:超越指南

获取原文
       

摘要

Recent updates to asthma guidelines from the Global Initiative for Asthma (GINA) and the National Asthma Education and Prevention Program (Expert Panel Report 3, EPR-3) share many similarities, reflecting a focus on asthma control based on clinical manifestations of disease and responsiveness to therapy. Both documents build upon the recommendations of former guidelines utilizing evidence-based review of the published literature to revise algorithms for practice. A major difference between the 2 reports is the preferred treatment at Step 3. The GINA guidelines recommend a combination of low-dose inhaled corticosteroid (ICS) plus long-acting β-agonist (LABA), whereas the EPR-3 advises either monotherapy with medium-dose ICS or the low-dose ICS + LABA combination. Both approaches are supported by clinical experience and Level A evidence. The option of personalized therapy is a point of discussion for future guidelines.
机译:全球哮喘病倡议(GINA)和美国国家哮喘教育和预防计划(Expert Panel Report 3,EPR-3)对哮喘指南的最新更新具有许多相似之处,反映出基于疾病和反应性临床表现的哮喘控制重点治疗。这两份文件均基于先前指南的建议,利用已发表文献的循证审查来修订实践算法。这2个报告之间的主要区别是在第3步中的首选治疗。GINA指南建议将低剂量吸入性皮质类固醇(ICS)与长效β激动剂(LABA)结合使用,而EPR-3建议采用单药治疗中剂量ICS或低剂量ICS + LABA组合。两种方法均得到临床经验和A级证据的支持。个性化治疗的选择是将来指南讨论的重点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号